Alloy is Building the World's First Fully Integrated Product Development
Organization - Read the full article
Ypsilon Receives $2.7 Million Non-Dilutive Grant to Advance Next-Generation TCRm Antibodies
Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) provides external validation of Ypsilon’s platform and lead asset
Discovery of highly-specific TCR mimic antibodies to WT1
Navigating high homology: Discovery of TCR mimic antibodies with greater specificity to Wilms tumor 1 antigen The development of TCR mimic (TCRm) antibodies (or TCR-like antibodies) offers a promising new approach for cancer immunotherapy but identifying TCRm antibody candidates with optimal specificity and low off-target effects can be challenging. Here, we look at an antibody […]
Keyway TCRm Discovery Webinar
Access the webinar recording Thanks for your interest in our recent Keyway TCR mimic Discovery webinar, Increasing Target Specificity and Tackling Intracellular Targets for TCRm Therapeutics Development with Keyway’s TCRm Discovery Offering. In it, the team at the helm of our TCR mimic discovery campaigns shared: 1. An overview of common challenges to intracellular protein-targeting drug discovery […]
High Efficiency CAR Discovery Screening
Alloy Therapeutics utilizes a high-efficiency CAR discovery and screening workflow that integrates the ATX-Gx™ humanized mouse platform with rapid cell-based functional assays to accelerate the identification of potent Chimeric Antigen Receptor (CAR) candidates. This streamlined approach enables researchers to optimize binder selection and validate CAR-T efficacy early in the drug development process to reduce timelines […]